Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Lifts JD HEALTH (06618.HK) TP to $68.8, Keeps Rating at Equalweight
Recommend 1 Positive 3 Negative 0 |
||||
|
||||
|
Morgan Stanley released a research report lifting its target price for JD HEALTH (06618.HK) from $60 to $68.8, based on a discounted cash flow valuation, with rating kept at Equalweight. After considering JD HEALTH's 3Q25 results, the broker believed that the Company benefits from growth in direct sales and service revenue, and raised its 2025-2027 total revenue forecasts by 1.4%. Furthermore, with the expansion of drug sales scale and higher proportion of advertising revenue, the Company's gross profit margin is on an uptrend. Morgan Stanley elevated its recurring EPS estimations for the period by 9%/ 13%/ 13% each. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
